Control of asthma in real life: Still a valuable goal?

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 361-369

  Papaioannou, Andriana I ^a   Kostikas, Konstantinos ^a   Zervas, Eleftherios ^b   Kolilekas, Lykourgos ^b   Papiris, Spiridon ^a   Gaga, Mina ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Athens Chest Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BUDESONIDE; CORTICOSTEROID; FORMOTEROL; LONG ACTING DRUG; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA CONTROL SCORING SYSTEM; ASTHMA CONTROL TEST; CLINICAL COMPETENCE; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; ENVIRONMENTAL EXPOSURE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HUMAN; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRACTICE GUIDELINE; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE ASSESSMENT; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFECTS; ECONOMICS; LUNG; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUESTIONNAIRE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; HUMANS; LUNG; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84930450089     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00001615     Document Type: Article

References (69)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Revised 2014. GINA, 2014. www.ginasthma.com
2. James AL, Knuiman MW, Divitini ML, et al. Changes in the prevalence of asthma in adults since 1966: the Busselton health study. Eur Respir J 2010; 35: 273–278.
3. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–478.
4. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59–99.
5. Pedersen S. From asthma severity to control: a shift in clinical practice. Prim Care Respir J 2010; 19: 3–9.
6. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma – Summary Report 2007. J Allergy Clin Immunol 2007; 120: Suppl 5, S94–S138.
7. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545–554.
8. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98: 1016–1018.
9. Yonas MA, Marsland AL, Emeremni CA, et al. Depressive symptomatology, quality of life and disease control among individuals with well-characterized severe asthma. J Asthma 2013; 50: 884–890.
10. Wertz DA, Pollack M, Rodgers K, et al. Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann Allergy Asthma Immunol 2010; 105: 118–123.
11. Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J 2007; 29: 56–62.
12. Vollmer WM, Markson LE, O’Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med 1999; 160: 1647–1652.
13. Chapman KR, Boulet LP, Rea RM, et al. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31: 320–325.
14. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802–807.
15. Chapman KR, Ernst P, Grenville A, et al. Control of asthma in Canada: failure to achieve guideline targets. Can Respir J 2001; 8: Suppl A, 35A–40A.
16. Boulet LP, Phillips R, O’Byrne P, et al. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J 2002; 9: 417–423.
17. Braido F. Failure in asthma control: reasons and consequences. Scientifica (Cairo) 2013; 2013: 549252.
18. Braido F, Baiardini I, Stagi E, et al. Unsatisfactory asthma control: astonishing evidence from general practitioners and respiratory medicine specialists. J Investig Allergol Clin Immunol 2010; 20: 9–12.
19. Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663–670.
20. Partridge MR, Hill SR. Enhancing care for people with asthma: the role of communication, education, training and self-management. 1998. World Asthma Meeting Education and Delivery of Care Working Group. Eur Respir J 2000; 16: 333–348.
21. Baiardini I, Braido F, Giardini A, et al. Adherence to treatment: assessment of an unmet need in asthma. J Investig Allergol Clin Immunol 2006; 16: 218–223.
22. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40–47.
23. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59–65.
24. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930–938.
25. Guidry GG, Brown WD, Stogner SW, et al. Incorrect use of metered dose inhalers by medical personnel. Chest 1992; 101: 31–33.
26. Gaga M, Papageorgiou N, Yiourgioti G, et al. Risk factors and characteristics associated with severe and difficult to treat asthma phenotype: an analysis of the ENFUMOSA group of patients based on the ECRHS questionnaire. Clin Exp Allergy 2005; 35: 954–959.
27. Taylor DR, Poulton R, Moffitt TE, et al. The respiratory effects of cannabis dependence in young adults. Addiction 2000; 95: 1669–1677.
28. Doshi V, Shenoy S, Ganesh A, et al. Profile of acute asthma exacerbation in drug users. Am J Ther 2014 [In press DOI: 10.1097/MJT.0000000000000118].
29. Price D, Dale P, Elder E, et al. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. J Asthma 2014; 51: 127–135.
30. Scadding G, Walker S. Poor asthma control? – then look up the nose. The importance of co-morbid rhinitis in patients with asthma. Prim Care Respir J 2012; 21: 222–228.
31. Wong CH, Chua CJ, Liam CK, et al. Gastro-oesophageal reflux disease in ‘difficult-to-control’ asthma: prevalence and response to treatment with acid suppressive therapy. Aliment Pharmacol Ther 2006; 23: 1321–1327.
32. Teodorescu M, Polomis DA, Teodorescu MC, et al. Association of obstructive sleep apnea risk or diagnosis with daytime asthma in adults. J Asthma 2012; 49: 620–628.
33. 33 ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26: 812–818.
34. Cruz AA, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA2LEN. Allergy 2007; 62: Suppl. 84, 1–41.
35. Gaga M, Lambrou P, Papageorgiou N, et al. Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 2000; 30: 663–669.
36. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161: 2051–2057.
37. Mastronarde JG. Is there a relationship between GERD and asthma? Gastroenterol Hepatol 2012; 8: 401–403.
38. Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J 2009; 33: 897–906.
39. Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173: 1091–1097.
40. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthma in adults and children. Cochrane Database Syst Rev 2003; 2: CD001496.
41. Lafond C, Sériès F, Lemière C. Impact of CPAP on asthmatic patients with obstructive sleep apnoea. Eur Respir J 2007; 29: 307–311.
42. Boulay ME, Boulet LP. Discordance between asthma control clinical, physiological and inflammatory parameters in mild asthma. Respir Med 2013; 107: 511–518.
43. Juniper EF, Chauhan A, Neville E, et al. Clinicians tend to overestimate improvements in asthma control: an unexpected observation. Prim Care Respir J 2004; 13: 181–184.
44. Juniper EF, Svensson K, Mörk AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553–558.
45. LeBlanc A, Robichaud P, Lacasse Y, et al. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy 2007; 62: 120–125.
46. Lara M, Edelen MO, Eberhart NK, et al. Development and validation of the RAND Asthma Control Measure. Eur Respir J 2014; 44: 1243–1252.
47. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–1721.
48. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483–494.
49. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
50. 50 de Jongste JC, Carraro S, Hop WC, et al. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009; 179: 93–97.
51. Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008; 31: 539–546.
52. Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181: 1033–1041.
53. Michils A, Louis R, Peché R, et al. Exhaled nitric oxide as a marker of asthma control in smoking patients. Eur Respir J 2009; 33: 1295–1301.
54. Papaioannou AI, Minas M, Tanou K, et al. Exhaled NO may predict loss of asthma control: the effect of concomitant allergic rhinitis. Eur Respir J 2009; 34: 1006–1007.
55. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378: 983–990.
56. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32–42.
57. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–1411.
58. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836–844.
59. 2-agonists in achieving asthma control. Chest 2008; 134: 1192–1199.
60. Matsunaga K, Kawabata H, Hirano T, et al. Difference in time-course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulm Pharmacol Ther 2013; 26: 189–194.
61. Lai CK, De Guia TS, Kim YY, et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol 2003; 111: 263–268.
62. Cazzoletti L, Marcon A, Janson C, et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007; 120: 1360–1367.
63. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000. European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24: 14009.
64. Gaga M, Papageorgiou N, Zervas E, et al. Control of asthma under specialist care: is it achieved? Chest 2005; 128: 78–84.
65. Gaga M, Zervas E. Breathing for two: pregnancy, asthma and respiratory failure. Eur Respir Rev 2014; 23: 5–7.
66. Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir Med 2012; 106: 205–214.
67. Yildiz F, ASIT Study Group. Factors influencing asthma control: results of a real-life prospective observational asthma inhaler treatment (ASIT) study. J Asthma Allergy 2013; 6: 93–101.
68. Sullivan SD, Wenzel SE, Bresnahan BW, et al. Association of control and risk of severe asthma-related events in severe or difficult-to-treat asthma patients. Allergy 2007; 62: 655–660.
69. Accordini S, Corsico AG, Braggion M, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013; 160: 93–101.